Page results
-
A front page story and patient case study highlight SUMMIT Study early diagnosis outcomes.
-
Breathing aids developed by engineers at UCL, UCLH and Mercedes-AMG High Performance Powertrains have been delivered to 40 NHS hospitals across the country.
-
Patients recovering from coronavirus have spoken movingly about the physical and emotional legacy of the disease.
-
UCLH is to work in partnership with University Hospitals Birmingham NHS Foundation Trust in a major digital health initiative in which researchers use data collected in acute care settings to improve patient care.
-
We’re delighted to announce that our Grafton Way Elective Surgical Hub has been successfully accredited as an elective surgical hub delivering high standards in clinical and operational practice.
-
This page is for patients who are doing a breath test at home for either fructose or lactose malabsorption.
-
UCLH and UCL neurologists have published the first clinical observations of patients who experienced an ischaemic stroke, the most common form of stroke, following an Oxford AstraZeneca vaccine.
-
Read more about the Halcyon linear accelerator, aimed at making cancer treatment faster, more comfortable, and more precise for patients.
-
More than 800 patients on waiting lists for Ear, Nose and Throat appointments across North Central London seen in two days during ENT surgery ‘super-weekend’
-
A BBC One documentary featuring clinicians at UCLH which airs this Thursday highlights the harm to the body and brain caused by ultra-processed food.
File results
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment
-
FOI/2022/0540 - Electronic patient record
-
FOI/2022/0541 - Serious Incidents Level 2 deaths/ serious harm
-
FOI/2022/0576 - Medications within dermatology